Cargando…

Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States

This open-label, phase 1/1b study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of fruquintinib in United States (U.S.) patients to confirm the recommended phase 2 dose (RP2D) established in China. Patients with advanced solid tumors who had progressed on approved sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang-Gillam, Andrea, Schelman, William, Ukrainskyj, Stacey, Chien, Caly, Gonzalez, Martha, Yang, Zhao, Kania, Marek, Yeckes-Rodin, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663261/ https://www.ncbi.nlm.nih.gov/pubmed/37796398 http://dx.doi.org/10.1007/s10637-023-01395-y

Ejemplares similares

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
por: Lin, Chia-Chi, et al.
Publicado: (2019)

An Open‐label Phase 1 Dose‐escalation Clinical Trial of a Single Intravenous Administration of Gemcitabine in Dogs with Advanced Solid Tumors
por: Marconato, L., et al.
Publicado: (2015)

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors
por: Minami, Hironobu, et al.
Publicado: (2016)

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
por: Bendell, Johanna C, et al.
Publicado: (2015)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
por: Hong, D S, et al.
Publicado: (2019)

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
por: Loeb, David M., et al.
Publicado: (2022)

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
por: von Mehren, Margaret, et al.
Publicado: (2014)

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023)

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
por: Marshall, John, et al.
Publicado: (2012)

MON-282 Treatment of Hyperprolactinemia with Ropinirole: An Open-Label Dose Escalation Study
por: Tsang, Amanda, et al.
Publicado: (2020)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
por: Kümler, I., et al.
Publicado: (2018)

Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
por: Liu, Shuai, et al.
Publicado: (2022)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
por: Li, Qingli, et al.
Publicado: (2022)

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
por: Twelves, Chris, et al.
Publicado: (2019)

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
por: Zhao, Wensi, et al.
Publicado: (2023)

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
por: Gordon, Michael S., et al.
Publicado: (2012)

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
por: Song, Yan, et al.
Publicado: (2021)

PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
por: Zhang, Hong-Qiang, et al.
Publicado: (2022)

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
por: Rudin, Charles M, et al.
Publicado: (2023)

Case report: PRES associated with fruquintinib in a patient with metastatic colon cancer
por: Wang, Lu, et al.
Publicado: (2023)

Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
por: Chen, Qiuyan, et al.
Publicado: (2018)

P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS
por: Ali, H., et al.
Publicado: (2022)

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
por: Tsai, Hui-Jen, et al.
Publicado: (2021)

Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study
por: Lorenz, Hanns-Martin, et al.
Publicado: (2011)

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
por: Li, Tianhong, et al.
Publicado: (2016)

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
por: Song, Yan, et al.
Publicado: (2021)

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
por: Dasari, Arvind, et al.
Publicado: (2023)

Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials
por: Mao, C., et al.
Publicado: (2023)

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
por: Peng, Zhi, et al.
Publicado: (2020)

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer
por: Shu, Yefei, et al.
Publicado: (2021)

Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol
por: Cheon, Chunhoo, et al.
Publicado: (2018)

Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study
por: Goto, Hideki, et al.
Publicado: (2022)

PB2349: A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES
por: Olszewski, Adam, et al.
Publicado: (2023)

Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review
por: Xu, Xiaojing, et al.
Publicado: (2022)

Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer
por: Nukatsuka, Mamoru, et al.
Publicado: (2023)

Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
por: Jones, Simon A., et al.
Publicado: (2017)

Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
por: Kudo, Toshihiro, et al.
Publicado: (2020)

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l31jhs8gftgjcp8idh9g6gehho